{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SOC%29&page=15", "query": { "intervention": "Standard of Care (SOC)", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 1108, "total_pages": 111, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SOC%29&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Standard+of+Care+%28SOC%29&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T19:42:55.412Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02355080", "title": "A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Substance-related Disorders" ], "interventions": [ { "name": "On-site bundled rapid HIV/HCV testing", "type": "BEHAVIORAL" }, { "name": "Standard of care (SOC)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2016-04", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02355080" }, { "nct_id": "NCT02952586", "title": "Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Chemoradiation", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 697, "start_date": "2016-11-28", "completion_date": "2020-08-25", "has_results": true, "last_update_posted_date": "2021-09-22", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 139, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 91 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02952586" }, { "nct_id": "NCT05362929", "title": "Efficacy and Tolerability of a Hybrid Fractional Laser for the Treatment of Acne Scars in Patients With Skin of Color", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acne Scars - Mixed Atrophic and Hypertrophic", "Hyperpigmentation", "Laser-Induced Hyperpigmentation" ], "interventions": [ { "name": "Sciton Halo", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Montefiore Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2023-10-11", "completion_date": "2029-07", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 1, "location_summary": "Elmsford, New York", "locations": [ { "city": "Elmsford", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05362929" }, { "nct_id": "NCT05489237", "title": "First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrointestinal Neoplasms", "Gastrointestinal Stromal Tumor (GIST)", "Digestive System Disease", "Gastrointestinal Diseases", "Metastatic Cancer" ], "interventions": [ { "name": "IDRX-42", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IDRX, Inc., a wholly owned subsidiary of GSK, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 276, "start_date": "2022-08-03", "completion_date": "2027-03-26", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 8, "location_summary": "Miami, Florida • Chicago, Illinois • Boston, Massachusetts + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05489237" }, { "nct_id": "NCT01208142", "title": "Toe Walker Gait Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Gait" ], "interventions": [ { "name": "standard of care treatment", "type": "OTHER" }, { "name": "Ankle Flexion Dynasplint", "type": "DEVICE" } ], "intervention_types": [ "OTHER", "DEVICE" ], "sponsor": "Dynasplint Systems, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 10, "start_date": "2010-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-08-12", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 2, "location_summary": "Columbus, Ohio • Lubbock, Texas", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01208142" }, { "nct_id": "NCT03775486", "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer NSCLC" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Placebo for Olaparib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nab-paclitaxel+carboplatin", "type": "DRUG" }, { "name": "Gemcitabine+carboplatin", "type": "DRUG" }, { "name": "Pemetrexed+carboplatin", "type": "DRUG" }, { "name": "Gemcitabine+cisplatin", "type": "DRUG" }, { "name": "Pemetrexed+cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 401, "start_date": "2018-12-21", "completion_date": "2026-09-27", "has_results": true, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 9, "location_summary": "Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more", "locations": [ { "city": "Bonita Springs", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tallahassee", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03775486" }, { "nct_id": "NCT05060432", "title": "Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Cancer", "Lung Cancer", "Head and Neck Cancer", "Melanoma" ], "interventions": [ { "name": "EOS-448", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "inupadenant", "type": "DRUG" }, { "name": "Dostarlimab", "type": "DRUG" }, { "name": "SOC chemotherapies", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "iTeos Belgium SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2021-09-06", "completion_date": "2025-07", "has_results": false, "last_update_posted_date": "2024-06-21", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 2, "location_summary": "San Diego, California • Bergen, New Jersey", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Bergen", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05060432" }, { "nct_id": "NCT04579393", "title": "Fostamatinib for Hospitalized Adults With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronavirus Disease 2019" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "fostamatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2020-10-08", "completion_date": "2021-04-30", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Falls Church, Virginia", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Falls Church", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04579393" }, { "nct_id": "NCT05631093", "title": "A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ART", "type": "DRUG" }, { "name": "DOR/ISL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 553, "start_date": "2023-02-20", "completion_date": "2028-07-11", "has_results": true, "last_update_posted_date": "2025-11-21", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 15, "location_summary": "Los Angeles, California • Palm Springs, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ft. Pierce", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05631093" }, { "nct_id": "NCT07059975", "title": "UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Pediatric AML" ], "interventions": [ { "name": "Idarubicin Hydrochloride", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine (Ara-C)", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Asparaginase Erwinia Chrysanthemi (recombinant)", "type": "DRUG" }, { "name": "Intrathecal triple", "type": "DRUG" }, { "name": "SOC", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Month to 30 Years" }, "enrollment_count": 36, "start_date": "2025-10-22", "completion_date": "2031-08", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-19T19:42:55.412Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07059975" } ] }